---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-010100"
form_type: "8-K"
ticker: "ADMA"
cik: "0001368514"
company_name: "ADMA BIOLOGICS, INC."
filed_at: "2024-02-28T23:59:59+00:00"
generated_at: "2026-06-05T08:29:01.715810+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ADMA Biologics CFO Brian Lenz steps down; CEO Grossman named interim CFO

## Summary
- CFO Brian Lenz transitions to consulting role effective April 1, 2024; consulting agreement through March 31, 2025.
- CEO Adam Grossman appointed Interim CFO; executive search initiated for permanent replacement.
- Grossman's 2024 base salary set at $800,000; awarded 557,728 RSUs and options for 870,950 shares at $5.40.
- Lenz receives $334,875 cash bonus for 2023 performance (141% of corporate goals achieved).

## SEC filing metadata
- accession: 0001140361-24-010100
- form_type: 8-K
- ticker: ADMA
- cik: 0001368514
- company_name: ADMA BIOLOGICS, INC.
- filed_at: 2024-02-28T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1368514/000114036124010100/0001140361-24-010100-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1368514/000114036124010100/ef20022642_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-010100
- JSON: https://secwatch.observer/filing/0001140361-24-010100.json
- Plain text: https://secwatch.observer/filing/0001140361-24-010100.txt

## Key facts
- Executive change
  Brian Lenz changed role as Chief Financial Officer at ADMA BIOLOGICS, INC..
  - Action: transitioned
  - Role: Chief Financial Officer
  source text: Effective as of April 1, 2024, Brian Lenz, Executive Vice President, Chief Financial Officer & General Manager, ADMA BioCenters, will transition from these positions to a consulting role with the Company (the “CFO Transition”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1368514/000114036124010100/0001140361-24-010100-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.